In Vivo Predictive Dissolution (iPD) Conference Rescheduled, Expanded

Ann Arbor, MI, February 9th, 2017: The *in vivo* Predictive Dissolution (iPD) Conference 2017, hosted by the Drug Delivery Foundation (www.ddfint.org) and originally proposed to be held at the University of Michigan August 7th – 9th, 2017, has been rescheduled and expanded to a four and a half day workshop March 5th – 9th, 2018, in Lake Tahoe, CA.

The rescheduling and expansion of the iPD conference was done to not conflict with the upcoming AAPS workshop in September and to provide more extensive education and training for implementing a science-based mechanistic Formulation Predictive Dissolution (fPD) methodology for a Pharmaceutical Product Development environment.

Details of the iPD-fPD four and a half day workshop will be available by September 2017, which will follow the format of the Oral Drug Delivery conference series that have been sponsored by the Drug Delivery Foundation over the past 30 years.

The Drug Delivery Foundation will also be a sponsor of the upcoming AAPS Dissolution workshop, held September 11th & 12th, 2017, in Washington DC. While the iPD-fPD workshop details will be available by September 2017, you can also contact the Drug Delivery Foundation and DDF Project Manager Drew Hertig at ahertig@ddfint.org and through the DDF website at www.ddfint.org.

About the Expanded Workshop: The iPD-fPD workshop will focus on Oral Formulation Predictive Dissolution (fPD) and the most recent results of human gastrointestinal physiological studies of the variables controlling oral drug absorption from an oral product. Development of an *in vitro* Predictive Dissolution methodology is essential for any simulation of absorption and blood levels to have *in vivo* relevance.

The scientific basis for setting up an fPD methodology will be presented in enough detail to allow companies to develop, evaluate and select formulations, including controlled or extended release systems, and assure a successful *in vivo* bioequivalence (BE) human study. An fPD can significantly reduce the number of human studies required to successfully pass a human BE test.

About the Drug Delivery Foundation: We serve as an international, not-for-profit organization for promoting education, training and research in the drug delivery field. We have provided training to industry, regulatory, and academic scientists and organizations.